<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Renovorx Inc — News on 6ix</title>
<link>https://6ix.com/company/renovorx-inc</link>
<description>Latest news and press releases for Renovorx Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 29 Apr 2026 12:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/renovorx-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835b98f78dffbe2df11580d.webp</url>
<title>Renovorx Inc</title>
<link>https://6ix.com/company/renovorx-inc</link>
</image>
<item>
<title>RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET</title>
<link>https://6ix.com/company/renovorx-inc/news/renovorx-to-host-first-quarter-2026-financial-results-and-business-highlights-conference-call-on-may-14th-at-430-pm-et</link>
<guid isPermaLink="true">https://6ix.com/company/renovorx-inc/news/renovorx-to-host-first-quarter-2026-financial-results-and-business-highlights-conference-call-on-may-14th-at-430-pm-et</guid>
<pubDate>Wed, 29 Apr 2026 12:30:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that it will host its first quarter 2026 financial results and business highlights conference call on May 14, 2026, at 4:30 pm ET. Additional details will be available on the Investor Relations section of the Com</description>
</item>
<item>
<title>RenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual Meeting</title>
<link>https://6ix.com/company/renovorx-inc/news/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamptm-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/renovorx-inc/news/renovorx-announces-pharmacokinetic-and-pharmacodynamic-data-abstract-supporting-the-tamptm-therapy-platform-accepted-for-presentation-at-the-2026-asco-annual-meeting</guid>
<pubDate>Thu, 23 Apr 2026 12:30:00 GMT</pubDate>
<description>Accepted Abstract is a Sub-Study in RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial and Explores the TAMP™ Therapy Platform’s Potential to Increase Local Drug Potency and Reduce Systemic Exposure and Common Side Effects of ChemotherapyMOUNTAIN VIEW, Calif., April 23, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-deli</description>
</item>
<item>
<title>Clinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific Meeting</title>
<link>https://6ix.com/company/renovorx-inc/news/clinical-data-supporting-targeted-chemotherapeutic-delivery-via-renovorxs-tamptm-therapy-platform-presented-at-2026-sir-annual-scientific-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/renovorx-inc/news/clinical-data-supporting-targeted-chemotherapeutic-delivery-via-renovorxs-tamptm-therapy-platform-presented-at-2026-sir-annual-scientific-meeting</guid>
<pubDate>Tue, 14 Apr 2026 12:30:00 GMT</pubDate>
<description>Data Shows TAMP to be a Promising Approach for Local Delivery of Gemcitabine with Reduced Systemic Toxicity in Patients Diagnosed with Locally Advanced Pancreatic Cancer Metabolic Imaging, Used to Evaluate Therapeutic Outcome Following Treatment with TAMP, Shows a Notable Reduction in Tumor Activity Suggesting a Potential Treatment Response MOUNTAIN VIEW, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing inn</description>
</item>
<item>
<title>RenovoRx Secures First Notice of Allowance for Japanese Patent Covering its RenovoCath® Device for Targeted, Local Drug-Delivery via the Vasa Vasorum</title>
<link>https://6ix.com/company/renovorx-inc/news/renovorx-secures-first-notice-of-allowance-for-japanese-patent-covering-its-renovocathr-device-for-targeted-local-drug-delivery-via-the-vasa-vasorum</link>
<guid isPermaLink="true">https://6ix.com/company/renovorx-inc/news/renovorx-secures-first-notice-of-allowance-for-japanese-patent-covering-its-renovocathr-device-for-targeted-local-drug-delivery-via-the-vasa-vasorum</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>Patent Expands Protection for the Company’s RenovoCath Device, the Novel Dual-Occlusion Catheter-Based System RenovoRx Currently Holds a Strong and Growing</description>
</item>
<item>
<title>RenovoRx Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2026</title>
<link>https://6ix.com/company/renovorx-inc/news/renovorx-named-to-fast-companys-annual-list-of-the-worlds-most-innovative-companies-of-2026-5</link>
<guid isPermaLink="true">https://6ix.com/company/renovorx-inc/news/renovorx-named-to-fast-companys-annual-list-of-the-worlds-most-innovative-companies-of-2026-5</guid>
<pubDate>Wed, 01 Apr 2026 18:20:00 GMT</pubDate>
<description>RenovoRx Joins the Ranks of Google, Nvidia, Adidas, Walmart, and MoreMOUNTAIN VIEW, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that it has been named on Fast Company’s prestigious list of the World’s Most Innovative Companies of 2026 as number 10 in the medical device c</description>
</item>
<item>
<title>RenovoRx Reports Full Year 2025 Financial Results and Provides Business Update</title>
<link>https://6ix.com/company/renovorx-inc/news/renovorx-reports-full-year-2025-financial-results-and-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/renovorx-inc/news/renovorx-reports-full-year-2025-financial-results-and-provides-business-update</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>RenovoCath® Generates $1.1 Million in 2025 Revenue in First Full Year of Commercialization Phase III TIGeR-PaC Trial on Track for Enrollment Completion by the</description>
</item>
<item>
<title>RenovoRx Announces Key Phase III Milestone: TIGeR-PaC Trial Surpasses 100 Randomized Patients as Study Nears Completion of Enrollment</title>
<link>https://6ix.com/company/renovorx-inc/news/renovorx-announces-key-phase-iii-milestone-tiger-pac-trial-surpasses-100-randomized-patients-as-study-nears-completion-of-enrollment</link>
<guid isPermaLink="true">https://6ix.com/company/renovorx-inc/news/renovorx-announces-key-phase-iii-milestone-tiger-pac-trial-surpasses-100-randomized-patients-as-study-nears-completion-of-enrollment</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>TIGeR-PaC Trial Enrollment Remains on Track for Completion in First Half of 2026, with Final Data Expected in 2027 Select TIGeR-PaC Cancer Centers Now Using</description>
</item>
<item>
<title>RenovoRx Announces Closing of Oversubscribed $10 Million at Market Private Placement</title>
<link>https://6ix.com/company/renovorx-inc/news/renovorx-announces-closing-of-oversubscribed-dollar10-million-at-market-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/renovorx-inc/news/renovorx-announces-closing-of-oversubscribed-dollar10-million-at-market-private-placement</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>Company has the funding, business plan, leadership and infrastructure to propel achievement of upcoming commercial and clinical milestones MOUNTAIN VIEW,</description>
</item>
<item>
<title>RenovoRx to Host Fourth Quarter and Full Year 2025 Financial Results and Business Highlights Conference Call on March 30th at 4:30 p.m. ET</title>
<link>https://6ix.com/company/renovorx-inc/news/renovorx-to-host-fourth-quarter-and-full-year-2025-financial-results-and-business-highlights-conference-call-on-march-30th-at-430-pm-et</link>
<guid isPermaLink="true">https://6ix.com/company/renovorx-inc/news/renovorx-to-host-fourth-quarter-and-full-year-2025-financial-results-and-business-highlights-conference-call-on-march-30th-at-430-pm-et</guid>
<pubDate>Fri, 20 Mar 2026 12:30:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., March 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that it will host its fourth quarter and full year 2025 financial results and business highlights conference call on March 30, 2026, at 4:30 p.m. ET. Additional details will be available on the Investor Relations</description>
</item>
<item>
<title>RenovoRx Announces $10 Million at Market Private Placement</title>
<link>https://6ix.com/company/renovorx-inc/news/renovorx-announces-dollar10-million-at-market-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/renovorx-inc/news/renovorx-announces-dollar10-million-at-market-private-placement</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>Bolstered Cash Position Expected to Capitalize the Company’s Momentum Towards Important Milestones, Including Breakeven Operations and Trial Data</description>
</item>
<item>
<title>RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum</title>
<link>https://6ix.com/company/renovorx-inc/news/renovorx-advancing-renovocathr-adoption-at-us-cancer-centers-strengthening-clinical-and-commercial-momentum</link>
<guid isPermaLink="true">https://6ix.com/company/renovorx-inc/news/renovorx-advancing-renovocathr-adoption-at-us-cancer-centers-strengthening-clinical-and-commercial-momentum</guid>
<pubDate>Fri, 27 Feb 2026 13:30:00 GMT</pubDate>
<description>Over the past year, RenovoRx has Tripled Commercially Active U.S. Cancer Centers and Centers Requesting Access to RenovoCath, its FDA-Cleared Device Over 700 RenovoCath Procedures Successfully Completed Since FDA Clearance in 2014 Company Appoints Ramtin Agah, MD to the Additional Position of Executive Chairman to Support Continued Clinical Adoption and Commercial Growth MOUNTAIN VIEW, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life s</description>
</item>
<item>
<title>RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Radiology Annual Scientific Meeting</title>
<link>https://6ix.com/company/renovorx-inc/news/renovorx-announces-acceptance-of-clinical-data-abstract-at-2026-society-of-interventional-radiology-annual-scientific-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/renovorx-inc/news/renovorx-announces-acceptance-of-clinical-data-abstract-at-2026-society-of-interventional-radiology-annual-scientific-meeting</guid>
<pubDate>Thu, 26 Feb 2026 13:30:00 GMT</pubDate>
<description>Accepted Abstract Highlights Metabolic Response Observations Following Chemotherapeutic Drug-Delivery via the TAMP™ Therapy Platform in Patients Diagnosed with Locally Advanced Pancreatic CancerMOUNTAIN VIEW, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that a clinical dat</description>
</item>
<item>
<title>RenovoRx Establishes RenovoCath® Medical Advisory Board</title>
<link>https://6ix.com/company/renovorx-inc/news/renovorx-establishes-renovocath-medical-advisory-133000320</link>
<guid isPermaLink="true">https://6ix.com/company/renovorx-inc/news/renovorx-establishes-renovocath-medical-advisory-133000320</guid>
<pubDate>Tue, 10 Feb 2026 13:30:00 GMT</pubDate>
<description>Advisory Board Members Will Provide Strategic Clinical Insights to Further Advance the TAMP™ Therapy Platform in Clinical Indications of High Unmet Medical NeedMOUNTAIN VIEW, Calif., Feb. 10, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced the formation of a dedicated RenovoCath Medical Advis</description>
</item>
<item>
<title>RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer</title>
<link>https://6ix.com/company/renovorx-inc/news/renovorx-appoints-experienced-public-company-133000077</link>
<guid isPermaLink="true">https://6ix.com/company/renovorx-inc/news/renovorx-appoints-experienced-public-company-133000077</guid>
<pubDate>Thu, 05 Feb 2026 13:30:00 GMT</pubDate>
<description>Appointment Strengthens RenovoRx’s C-Suite Leadership to Support Commercial Growth of RenovoCath®MOUNTAIN VIEW, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, is pleased to announce the appointment of Mark Voll as the Company’s Chief Financial Officer, effective February 1, 2026. Mr. Voll b</description>
</item>
<item>
<title>RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting</title>
<link>https://6ix.com/company/renovorx-inc/news/renovorx-announces-clinical-data-supporting-133000177</link>
<guid isPermaLink="true">https://6ix.com/company/renovorx-inc/news/renovorx-announces-clinical-data-supporting-133000177</guid>
<pubDate>Wed, 04 Feb 2026 13:30:00 GMT</pubDate>
<description>Results Support TAMP’s Novel Approach to Targeted, Pressure-Mediated Chemotherapeutic Delivery and Reinforces its Potential to Provide Individualized, Optimized Drug-DeliveryMOUNTAIN VIEW, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that new clinical data will be presente</description>
</item>
<item>
<title>RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting</title>
<link>https://6ix.com/company/renovorx-inc/news/renovorx-announces-acceptance-clinical-data-133000162</link>
<guid isPermaLink="true">https://6ix.com/company/renovorx-inc/news/renovorx-announces-acceptance-clinical-data-133000162</guid>
<pubDate>Wed, 28 Jan 2026 13:30:00 GMT</pubDate>
<description>Accepted Abstract Provides Supportive Evidence for the TAMP™ Therapy Platform’s Novel Approach to Targeted, Pressure-Mediated Drug-Delivery via Additional Clinical DataMOUNTAIN VIEW, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that its abstract submission to the 2026 Soci</description>
</item>
<item>
<title>RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center</title>
<link>https://6ix.com/company/renovorx-inc/news/renovorx-expands-renovocath-commercial-adoption-133000174</link>
<guid isPermaLink="true">https://6ix.com/company/renovorx-inc/news/renovorx-expands-renovocath-commercial-adoption-133000174</guid>
<pubDate>Tue, 20 Jan 2026 13:30:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies, today announced continued commercial momentum with a growing number of U.S. cancer centers now integrating the Company’s RenovoCath patented FDA-cleared drug-delivery device into oncology treatment programs. The Company’s TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform, enabled by the RenovoCath de</description>
</item>
<item>
<title>RenovoRx to Participate in AlphaNorth Capital Event, January 16-18, 2026</title>
<link>https://6ix.com/company/renovorx-inc/news/renovorx-participate-alphanorth-capital-event-133000341</link>
<guid isPermaLink="true">https://6ix.com/company/renovorx-inc/news/renovorx-participate-alphanorth-capital-event-133000341</guid>
<pubDate>Wed, 14 Jan 2026 13:30:00 GMT</pubDate>
<description>CEO Shaun Bagai to Discuss RenovoRx’s Commercial and Clinical Program ProgressMOUNTAIN VIEW, Calif., Jan. 14, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (Nasdaq: RNXT) (“RenovoRx” or “the Company”), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that Chief Executive Officer Shaun Bagai will participate in the AlphaNorth Capital Event. The conference will be held from January 16-18,</description>
</item>
<item>
<title>RenovoRx To Announce Promising New Clinical Data Using its TAMP™ Therapy Platform in an Abstract to be Presented at ASCO GI 2026</title>
<link>https://6ix.com/company/renovorx-inc/news/renovorx-announce-promising-clinical-data-133000789</link>
<guid isPermaLink="true">https://6ix.com/company/renovorx-inc/news/renovorx-announce-promising-clinical-data-133000789</guid>
<pubDate>Thu, 08 Jan 2026 13:30:00 GMT</pubDate>
<description>New Pharmacokinetic (PK) and Pharmacodynamic Data from Sub-Study in Phase III Trial Strengthens Scientific Basis for RenovoRx’s TAMP Therapy Platform as a Targeted Drug-Delivery Approach Data Shows a PK Profile that May Improve Clinical Efficacy and Decrease Clinical Side Effects with TAMP and Intra-Arterial Gemcitabine Versus Standard of Care Chemotherapy MOUNTAIN VIEW, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company</description>
</item>
<item>
<title>RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026</title>
<link>https://6ix.com/company/renovorx-inc/news/renovorx-announces-acceptance-clinical-data-133000511</link>
<guid isPermaLink="true">https://6ix.com/company/renovorx-inc/news/renovorx-announces-acceptance-clinical-data-133000511</guid>
<pubDate>Thu, 11 Dec 2025 13:30:00 GMT</pubDate>
<description>The Accepted Abstract Provides Supportive Evidence for the TAMP™ Therapy Platform’s Novel, Localized Approach to Targeted Chemotherapeutic Delivery via Additional Pharmacokinetic and Pharmacodynamic DataMOUNTAIN VIEW, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, is pleased to announce tha</description>
</item>
</channel>
</rss>